HK1030540A1 - Synergistic effects of op/bmp morphogens and gdnf/ngf neurotrophic factors op/bmp - Google Patents
Synergistic effects of op/bmp morphogens and gdnf/ngf neurotrophic factors op/bmpInfo
- Publication number
- HK1030540A1 HK1030540A1 HK00108400A HK00108400A HK1030540A1 HK 1030540 A1 HK1030540 A1 HK 1030540A1 HK 00108400 A HK00108400 A HK 00108400A HK 00108400 A HK00108400 A HK 00108400A HK 1030540 A1 HK1030540 A1 HK 1030540A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- bmp
- gdnf
- cells
- vivo
- neurotrophic factors
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1875—Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Physical Education & Sports Medicine (AREA)
- Psychology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Zoology (AREA)
- Vascular Medicine (AREA)
- Immunology (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US5825897P | 1997-09-09 | 1997-09-09 | |
PCT/US1998/018772 WO1999012560A1 (en) | 1997-09-09 | 1998-09-09 | Synergistic effects of op/bmp morphogens and gdnf/ngf neurotrophic factors |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1030540A1 true HK1030540A1 (en) | 2001-05-11 |
Family
ID=22015678
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK00108400A HK1030540A1 (en) | 1997-09-09 | 2000-12-23 | Synergistic effects of op/bmp morphogens and gdnf/ngf neurotrophic factors op/bmp |
Country Status (9)
Country | Link |
---|---|
EP (1) | EP1011711B1 (xx) |
JP (3) | JP2001515867A (xx) |
AT (1) | ATE363914T1 (xx) |
AU (1) | AU749454B2 (xx) |
CA (1) | CA2303460C (xx) |
DE (1) | DE69837885T2 (xx) |
ES (1) | ES2288766T3 (xx) |
HK (1) | HK1030540A1 (xx) |
WO (1) | WO1999012560A1 (xx) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE69821629T2 (de) | 1997-09-19 | 2005-01-13 | Biopharm Gesellschaft Zur Biotechnologischen Entwicklung Von Pharmaka Mbh | Kombinationen von Cytokinen mit neurotroper Aktivität |
US20030170213A1 (en) * | 1998-01-23 | 2003-09-11 | Marc F. Charette | Methods and compositions for enhancing cognitive function using morphogenic proteins |
DE19816186A1 (de) * | 1998-04-14 | 1999-10-21 | Univ Muenchen L Maximilians | GDNF-kodierende DNA, Teile davon und GDNF-Varianten |
JP4834224B2 (ja) | 1999-03-05 | 2011-12-14 | デューク ユニバーシティ | C16不飽和fp−選択的プロスタグランジン類縁体 |
US20020172693A1 (en) | 2000-03-31 | 2002-11-21 | Delong Michell Anthony | Compositions and methods for treating hair loss using non-naturally occurring prostaglandins |
US20020013294A1 (en) | 2000-03-31 | 2002-01-31 | Delong Mitchell Anthony | Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives |
US7922999B2 (en) * | 2006-04-25 | 2011-04-12 | The Regents Of The University Of California | Administration of growth factors for the treatment of CNS disorders |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU4424996A (en) * | 1994-12-14 | 1996-07-03 | Amgen Boulder Inc. | A tgf-beta superfamily type ii receptor having binding affinity |
US6048964A (en) * | 1995-12-12 | 2000-04-11 | Stryker Corporation | Compositions and therapeutic methods using morphogenic proteins and stimulatory factors |
-
1998
- 1998-09-09 AT AT98948122T patent/ATE363914T1/de not_active IP Right Cessation
- 1998-09-09 EP EP98948122A patent/EP1011711B1/en not_active Expired - Lifetime
- 1998-09-09 DE DE69837885T patent/DE69837885T2/de not_active Expired - Lifetime
- 1998-09-09 JP JP2000510457A patent/JP2001515867A/ja not_active Withdrawn
- 1998-09-09 CA CA2303460A patent/CA2303460C/en not_active Expired - Lifetime
- 1998-09-09 AU AU94759/98A patent/AU749454B2/en not_active Ceased
- 1998-09-09 WO PCT/US1998/018772 patent/WO1999012560A1/en active IP Right Grant
- 1998-09-09 ES ES98948122T patent/ES2288766T3/es not_active Expired - Lifetime
-
2000
- 2000-12-23 HK HK00108400A patent/HK1030540A1/xx not_active IP Right Cessation
-
2009
- 2009-06-16 JP JP2009143767A patent/JP5075877B2/ja not_active Expired - Fee Related
-
2012
- 2012-04-06 JP JP2012087469A patent/JP5550673B2/ja not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
JP5550673B2 (ja) | 2014-07-16 |
JP2012131832A (ja) | 2012-07-12 |
ATE363914T1 (de) | 2007-06-15 |
CA2303460A1 (en) | 1999-03-18 |
AU9475998A (en) | 1999-03-29 |
CA2303460C (en) | 2011-06-21 |
DE69837885D1 (de) | 2007-07-19 |
AU749454B2 (en) | 2002-06-27 |
JP5075877B2 (ja) | 2012-11-21 |
JP2001515867A (ja) | 2001-09-25 |
ES2288766T3 (es) | 2008-01-16 |
JP2009209152A (ja) | 2009-09-17 |
EP1011711B1 (en) | 2007-06-06 |
EP1011711A1 (en) | 2000-06-28 |
DE69837885T2 (de) | 2008-02-07 |
WO1999012560A1 (en) | 1999-03-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Wang et al. | Use of carnosine as a natural anti-senescence drug for human beings | |
AU2782499A (en) | Isolated stromal cells for use in the treatment of diseases of the central nervous system | |
GB9807639D0 (en) | Anti-inflammatory agents | |
BR0013905A (pt) | Uso de um ingrediente ativo, composição farmacêutica, métodos para induzir secreção g-csf dentro do corpo de um indivìduo, para tratamento terapêutico, para induzir a proliferação ou diferenciação de medula óssea ou células brancas do sangue em um indivìduo, para a prevenção ou tratamento de leucopenia, para a prevenção ou tratamento de efeitos colaterais tóxicos de uma droga, para inibir o crescimento anormal de células, para o tratamento de câncer, e, uso de a3rag | |
BR0307871A (pt) | Proteìnas contendo domìnio de folistatina | |
WO2001064238A3 (en) | Methods and compositions for regulating adipocytes | |
BR0315645A (pt) | Polipetìdeos de fusão de actrib e seus usos | |
BR9910251A (pt) | Estimulação hematopoiética | |
PL339745A1 (en) | Agonists of apolipoprotein a-1 and their application in treating dislipidemic disorders | |
HK1049350A1 (en) | Multipotent adult stem cells and methods for isolation | |
DE69232008D1 (de) | Verwendung von insulinähnlichen Wachstumsfaktoren und Analogen zur BEHANDLUNG VON ERKRANKUNGEN DER SEHNERVEN | |
WO1999010004A3 (en) | Regulation of muscle tissues by hedgehog-like polypeptides, and formulations and uses related thereto | |
DE69635924D1 (de) | Isolierung und züchtung von schwannzellen | |
HK1030540A1 (en) | Synergistic effects of op/bmp morphogens and gdnf/ngf neurotrophic factors op/bmp | |
Zhou et al. | Protective effect of nerve growth factor on neurons after traumatic brain injury | |
WO2000015246A3 (en) | Regulation of lung tissue by hedgehog-like polypeptides, and formulations and uses related thereto | |
IL123642A (en) | Pharmaceutical compositions comprising mononuclear phagocytes to promote axonal regeneration | |
ES2162331T3 (es) | Utilizacion del factor de crecimiento del tejido nervioso para conservacion, cultivo o tratamiento de la cornea. | |
WO2007014156A3 (en) | Fibroblast growth factor-2 promotes neurogenesis and neuroprotection and prolongs survival in huntington's disease | |
KR101375783B1 (ko) | 백반증 예방 또는 치료용 조성물 | |
GR3018632T3 (en) | Beta-alethine use in cell culture and therapy. | |
Yang et al. | Effect of steroidal saponins-loaded nano-bioglass/phosphatidylserine/collagen bone substitute on bone healing | |
AU7500200A (en) | Combined therapies for atherosclerosis treatment | |
Vvedenskiy et al. | Effect of Cryopreserved Cord Blood Serum Administration on Structural Changes of Joints During Induced Gonarthrosis in Rats | |
Rosenberg-Schaffer | An in vitro study of the effects of methylprednisolone on lesioned and uninjured mammalian spinal cord neurons. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20160909 |